KURA.NASDAQKura Oncology, INC

Form 4: Kura Oncology Director Mary Szela Granted 28,500 Stock Options

Sentiment:

Insider Transaction Report

📋All filings for Kura Oncology, INC
🔒Login to Follow

Kura Oncology, Inc. director Mary T. Szela was granted 28,500 stock options with an exercise price of $6.57, vesting in full on June 5, 2026.

Summary

  • Mary T. Szela, a Director of Kura Oncology, Inc. (KURA), was granted 28,500 options to purchase common stock.
  • The transaction date for this grant was June 5, 2025.
  • The exercise price for these options is $6.57 per share.
  • The options will vest in full on the one-year anniversary of the grant date, which is June 5, 2026.
  • The expiration date for these options is June 4, 2035.
  • Following this transaction, Mary T. Szela beneficially owns 28,500 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive for aligning interests, but it's a routine compensation event and doesn't indicate significant operational news.

Positives

  • The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.

Negatives

  • No specific negative information is contained within this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing, detailing an equity grant to a director, is a routine disclosure for publicly traded companies and does not provide broader industry context or trends.

Related Party Transactions

  • The grant of stock options to a director (Mary T. Szela) by Kura Oncology, Inc. constitutes a related party transaction, as it involves compensation provided to an insider.

Stakeholder Impact

  • Shareholders: The option grant aligns the director's financial interests with long-term shareholder value creation.
  • Employees: No direct impact on general employees is indicated by this filing.

Key Dates

DateDescription
06/05/2025Date of earliest transaction (grant of stock options).
06/06/2025Signature date of the reporting person's attorney-in-fact.
06/05/2026One-year anniversary of the grant date, when the options vest in full.
06/04/2035Expiration date of the stock options.

Recommendation

hold

Keywords

Kura Oncology, KURA, Form 4, SEC Filing, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Beneficial Ownership, Mary Szela

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.